Quantity | = | Concentration | x | Volume | x | Molecular Weight |
---|---|---|---|---|---|---|
= | x | x |
1) Click the Molarity Calculation Cart® button.
2) Specify the Concentration and Volume of your desired Molarity.
3) Click Calculate.
4) Your desired Quantity will be calculated and will be put under Quantity: (only for mg)
5) Click Add to Cart and then Proceed to checkout to complete the order. You will receive the quantity as you ordered as solvent-free form.
Alert: If you want to make a solution with a solvent (such DMSO), please add instructions in the notes section (such as 10 nM/1 mL in DMSO) and we will pack and deliver the product as a solution (such as 10 nM solution in 1 mL DMSO). If the product cannot be dissolved in DMSO or you would like to specify your own preferred solvent, please add detailed instructions in the notes section. All solutions must be shipped with an ice bag, costing an additional fee of $20 for S&H.
AOB87361
CAS No:1204918-72-8 (937270-47-8)
Warning: Last items in stock!
Availability date:
Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
---|---|---|---|
1 | 100 | $11.25 | Total: $1,125.00 |
1 | 50 | $13.00 | Total: $650.00 |
1 | 25 | $15.25 | Total: $381.25 |
1 | 10 | $18.00 | Total: $180.00 |
1 | 5 | $21.25 | Total: $106.25 |
Molecular Formula | C23H24N4O |
Molecular Weight | 372.46 |
CAS Numbers | 1204918-72-8 |
Storage Condition | 0°C (short term), -20°C (long term), desiccated |
Solubility | DMSO |
Purity | 98% by HPLC |
Synonym | Ex45; Ex-45; EX 45; TG02; TG 02; TG02; SB1317; SB1317; SB 1317; Zotiraciclib; Zotiraciclib free base; |
IUPAC/Chemical Name | 20-Oxa-5,7,14,27-tetraazatetracyclo[19.3.1.12,6.18,12]heptacosa-1(25),2,4,6(27),8,10,12(26),16,21,23-decaene, 14-methyl- |
InChl Key | VXBAJLGYBMTJCY-NSCUHMNNSA-N |
InChl Code | InChI=1S/C23H24N4O/c1-27-13-3-2-4-14-28-21-10-6-8-19(16-21)22-11-12-24-23(26-22)25-20-9-5-7-18(15-20)17-27/h2-3,5-12,15-16H,4,13-14,17H2,1H3,(H,24,25,26)/b3-2+ |
SMILES Code | CN(C/C=C/CCO1)CC2=CC(NC3=NC(C4=CC1=CC=C4)=CC=N3)=CC=C2 |
References | 1) Pallis M, Abdul-Aziz A, Burrows F, Seedhouse C, Grundy M, Russell N. The multi-kinase inhibitor TG02 overcomes signalling activation by survival factors to deplete MCL1 and XIAP and induce cell death in primary acute myeloid leukaemia cells. Br J Haematol. 2012 Oct;159(2):191-203. 2) Poulsen A, et al., Dymock B. Structure-based design of nitrogen-linked macrocyclic kinase inhibitors leading to the clinical candidate SB1317/TG02, a potent inhibitor of cyclin dependant kinases (CDKs), Janus kinase 2 (JAK2), and Fms-like tyrosine kinase-3 (FLT3). J Mol Model. 2013 Jan;19(1):119-30. |
A CDK, JAK and FLT inhibitor